Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | LPAR3 | Q9UBY5 | 8/20 | 0.58 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.58 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.42 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29177519 | 0.97 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL15389152 | 0.97 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL26559 | 0.97 | CYP3A4 (0.64) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL6684785 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL15232926 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| Phosphoric Acid SCHEMBL3940342 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL673594 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL1498124 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL9584742 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL9854018 | 0.95 | CYP3A4 (0.61) | CYP3A4LPAR3LPAR2LPAR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868162-B2 | Antimicrobial and antiviral compounds and methods for their use | LAKEWOOD-AMEDEX, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20070053971-A1 | Antimicrobial and Antiviral Compounds and Methods for their Use | OLIGOS ETC., INC | 2007-03-08 | — | — | US | disclosed |
| US-7176191-B2 | Antimicrobial compounds and methods for their use | OLIGOS ETC. INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070053971-A1 | Antimicrobial and Antiviral Compounds and Methods for their Use | MAVS, ITPA, STING1 | CYP3A4 1266/4885LPAR3 1796/4885LPAR2 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.